TARGET PharmaSolutions stands as a beacon in the healthcare industry, continuously pushing the boundaries of collaborative clinical data to enhance patient outcomes. Established in February 2015, it builds on the successful foundation of HCV-TARGET, a pioneering Hepatitis C initiative that began in 2011 under the guidance of Dr. Michael Fried and Dr. David Nelson.
With the backing of $27 million in funding, HCV-TARGET effectively manages over 6,000 patient cases, collaborating with 50 clinical sites. Notably, it enjoys a formal partnership with the FDA, indicating a significant level of trust and validation from regulatory authorities. This collaboration has led to successful expansions of product labels and reduced Phase IV obligations for sponsors.
TARGET PharmaSolutions attracted a Series A investment on December 1, 2016, with support from VentureSouth and Rex Health Ventures. This financial milestone underscores its potential as a transformative player in healthcare.
